PPD has put its medical affairs research operations (MARO) team under Evidera, the real-world research-focused subsidiary PPD bought last year.
The new unit, with Evidera’s name, will still be focusing on real-world research for regulatory approval, as well as market access communications and consulting.
“Our focus is to better anticipate post-approval requirements in order to further enhance trial designs and increase the efficiency and effectiveness of providing crucial data for market access activities,” PPD’s spokeperson Randy Buckwalter told FierceCRO.
Buckwalter said the company has seen a great deal of collaboration and alignment between the two organizations since PPD’s acquisition of Evidera last August.
This new unit “combines Evidera’s multidisciplinary scientific and consulting expertise to design studies, analyze findings and communicate outcomes, with PPD’s global operational infrastructure to manage and implement both interventional and observational studies,” he said.
Some other services it provides include health modeling and simulation to help analyze a drug’s economic value and impact, expanded access or compassionate use, clinical outcome assessments, safety and risk management, etc.
Jon Williams, president and CEO of Evidera since 2013, will lead the new unit. The members previously with the two teams will continue to work at their current locations, so the reorganization is more operational than physical, according to Buckwalter.
PPD also unveiled a new logo for Evidera in conjunction with the announcement.